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Abstract
Following an application from Nestle S.A. submitted for authorisation of a health claim pursuant to Article
13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on
Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific
substantiation of a health claim related to beta-glucans from oats and/or barley in a ready-to-eat cereal
manufactured via pressure cooking and reduction of blood glucose rise after consumption. The scope of
the application was proposed to fall under a health claim based on newly developed scientific evidence.
The food proposed is ‘beta-glucans from oats and/or barley incorporated into ready-to-eat breakfast
cereals manufactured via pressure cooking’. The applicant proposed that at least 1.3 g of beta-glucans/
25 g of available carbohydrates in ready-to-eat breakfast cereals manufactured via pressure cooking
should be consumed. Beta-glucans from oats, barley or any combination thereof incorporated into ready-
to-eat cereals manufactured by pressure cooking, are sufficiently characterised. The claimed effect
proposed is ‘reduction of the blood glucose rise after the meal’. The reduction of post-prandial glycaemic
responses (as long as post-prandial insulinaemic responses are not disproportionally increased) may be a
beneficial physiological effect. One human intervention study showed an effect of beta-glucans from oats
and/or barley, incorporated into breakfast cereals manufactured via pressure cooking at a level of at
least 1.2 g/25 g available carbohydrates, on decreasing post-prandial glycaemic responses without
disproportionally increasing insulinaemic responses. Dose–response relationships were not tested, and
no evidence has been provided that beta-glucans incorporated into cereals processed using pressure
cooking would exert a higher effect on post-prandial glucose responses than beta-glucans added to other
carbohydrate containing foods. Whereas the effect of beta-glucans in reducing post-prandial blood
glucose responses is well established, the evidence provided is insufficient to establish such an effect at
doses of 1.3 g beta-glucans per 25 g of available carbohydrate incorporated into ready-to-eat breakfast
cereals manufactured via pressure cooking (i.e. either batch cooking or extrusion).
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health), which are based on newly developed
scientific evidence or include a request for the protection of proprietary data, to the Community list of
permitted claims referred to in Article 13(3). According to Article 18 of this Regulation, an application
for inclusion in the Community list of permitted claims referred to in Article 13(3) shall be submitted by
the applicant to the national competent authority of a Member State, which will make the application
and any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: beta-glucans from oats and/or
barley in a ready-to-eat breakfast cereal contribute to a reduction of the blood glucose rise after that
meal.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of beta-glucans from oats and/or barley in a ready-to-eat breakfast cereal, a positive
assessment of its safety, nor a decision on whether beta-glucans from oats and/or barley in a ready-
to-eat breakfast cereal is, or is not, classified as a foodstuff. It should be noted that such an
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘beta-glucans sourced
from oats and/or barley, incorporated into ready-to-eat breakfast cereals manufactured via pressure
cooking (i.e. either by batch cooking or extrusion), and present at a level of at least 1.3 g per 25 g
available carbohydrate in the ready-to-eat cereal’.
Health relationship as claimed by the applicant
According to the applicant, the health effect is related to ‘reduction of the blood glucose rise after
the meal’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that ‘the mechanism by which beta-glucans from oats or barley could exert
the claimed effect is well established and relates to the increased viscosity of the meal bolus when
beta-glucans are added. When the meal bolus reaches the small intestine, a high viscosity delays the
rate of absorption of nutrients, including glucose. Ready-to-eat cereals that are manufactured via
pressurised batch cooking or extrusion, and containing oat or barley beta-glucans, are associated with
increased beta-glucan extractability and increased viscosity, both of which are postulated to have a
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greater effect on lowering the postprandial glucose response than the oat or barley ingredients
themselves (i.e. not incorporated into the batch-cooked or extruded cereals).’
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘consumption of beta-
glucans from oats and/or barley in a ready-to-eat breakfast cereal contributes to a reduction of the
blood glucose rise after that meal’.
Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is the general
population. The quantity of at least 1.3 g per 25 g available carbohydrates is recommended. The
quantity of beta-glucans can easily be integrated into one breakfast cereal serving. One serving of
cereal generally falls within the range of between 30 and 45 g.
Data provided by the applicant
The health claim application pursuant to Article 13.5 of Regulation 1924/2006 was presented in a
common and structured format as outlined in the Scientific and technical guidance for the preparation
and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2016).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA General guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientific requirements for health claims related to appetite ratings, weight management and
blood glucose concentrations are outlined in a specific EFSA guidance (EFSA NDA Panel, 2012).
The data claimed as proprietary are: unpublished clinical Study Reports: SUGiRS, 2018
(unpublished) and SUGiRS, 2019 (unpublished), and unpublished In Vitro Study Report Hyyti€ainen-
Pabst et al., 2019 (unpublished).
The data claimed as confidential are: In SUGiRS, (2018 unpublished) study report: table 1 p.6,
Results pp. 11-20, conclusions pp. 21-22; Appendices B-F. In SUGiRS (2019, unpublished) study
report: table 1 p. 5; results pp. 11-15; interpretation of findings p. 16; Appendices B-F; Report
#1912a: Table 1 p. 5; Results pp. 11-15; Interpretation of findings p. 16; Appendices B-F. EFSA has
issued its Decision on Confidentiality on 17/12/2020.
3. Assessment
The approach used by the NDA Panel for the evaluation of health claims is explained in the General
scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016). In assessing
each specific food/health relationship, which forms the basis of a health claim the NDA Panel considers
the following key questions:
i) the food/constituent is defined and characterised;
ii) the claimed effect is based on the essentiality of a nutrient; or the claimed effect is defined
and is a beneficial physiological effect for the target population and can be measured in vivo
in humans;
iii) a cause and effect relationship is established between the consumption of the food/constituent
and the claimed effect (for the target group under the proposed conditions of use).
Each of these three questions needs to be assessed by the NDA Panel with a favourable outcome
for a claim to be substantiated. In addition, an unfavourable outcome of the assessment of questions
(i) and/or (ii) precludes the scientific assessment of question (iii).
3.1. Characterisation of the food/constituent
The food/constituent proposed by the applicant as the subject of the health claim is ‘beta-glucans
sourced from oats and/or barley, incorporated into ready-to-eat breakfast cereals manufactured via
pressure cooking (i.e. either by batch cooking or extrusion), and present at a level of at least 1.3 g per
25 g available carbohydrate in the ready-to-eat cereal’.
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Beta-glucans are non-starch polysaccharides composed of glucose molecules in long linear glucose
polymers with mixed b-(1?4) and b-(1?3) links. Their molecular weight varies from 50 to 2,000 kDa.
Beta-glucans occur naturally in the bran of cereal grasses such as barley (ca. 7%), oats (ca. 5%), rye
and wheat (1–2%), and are measurable in foods by established methods. The mixed linkages are
important for their physical properties, such as solubility and viscosity. Their viscosity is a function of
the concentration of dissolved beta-glucans, of their molecular weight (Wood et al., 2000), and further
depends on differences in raw materials, processing and methods of determination.
In 2011, the EFSA NDA Panel evaluated a health claim on beta-glucans from oats and barley and
reduction of post-prandial glycaemic responses pursuant to Article 13(1) of Regulation (EC) No 1924/2006
with a favourable outcome (EFSA NDA Panel, 2011). The Panel considered that, in order to obtain the
claimed effect, 4 g of beta-glucans from oats or barley for each 30 g of available carbohydrate should be
consumed per meal.
In the present application, the applicant proposes that at least 1.3 g of beta-glucans per 25 g of
available carbohydrates in ready-to-eat breakfast cereals manufactured via pressure cooking (i.e. either
by batch cooking or extrusion) should be consumed in order to obtain the claimed effect. The
applicant claims that the reason for the lower amount of beta-glucans needed to exert the claimed
effect relative to the amount of available carbohydrates consumed is due to the manufacturing process
(i.e. the pressure cooking) of these ready-to-eat breakfast cereals.
Regarding the manufacturing process of the ready-to-eat breakfast cereals, batch cooking involves
the application of steam injected into a closed, pressurised vessel. Depending on the type of cereal,
the cooking time can range from 30 min to 2 h. Once the grains are cooked, the dough mixture is
shaped, dried and toasted to produce the finished cereal product. In contrast, for cereals prepared by
extrusion, the mixed ingredients are forced through a die and then cut into specific shapes; thus,
extrusion cooking involves subjecting the grain mixture to high pressure and high shear conditions, at
high temperature for just a short period of time. An overview of the manufacturing process and
information regarding stability of batches was provided by the applicant.
Upon a request from EFSA, the applicant clarified that the food constituent proposed as the subject
of the claim is beta-glucans from oats, barley or any combination thereof.
The Panel considers that the food constituent, beta-glucans from oats, barley or any combination
thereof, incorporated into ready-to-eat cereals manufactured by pressure cooking, which is the subject
of the health claim, is sufficiently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘reduction of the blood glucose rise after the meal’.
The proposed target population is the general population.
Claims on the reduction of post-prandial blood glucose responses refer to the ability of a food/
constituent to reduce the blood glucose rise after consumption of a food or meal rich in digestible
carbohydrates (i.e. in comparison to a reference food or meal). This ability may be considered a
beneficial physiological effect (e.g. for subjects with impaired glucose tolerance) as long as insulin
responses are not disproportionally increased.
The scientific evidence for the substantiation of health claims on the reduction of post-prandial
blood glucose responses can be obtained from human intervention studies showing a decrease in
blood glucose concentrations at different time points after consumption of the test food during an
appropriate period of time (i.e. at least 2 h) and no increase in insulin concentrations in comparison to
the reference food (EFSA NDA Panel, 2012).
The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-
prandial insulinaemic responses are not disproportionally increased) may be a beneficial physiological
effect.
3.3. Scientific substantiation of the claimed effect
The applicant performed a literature search on 29 April 2019 in the following databases: Adis
Clinical Trials Insight, Allied & Complementary MedicineTM, BIOSIS Previews®, CAB ABSTRACTS,
Embase®, Foodline®: Science, FSTA®, MEDLINE® and NTIS: National Technical Information Service.
Keywords used for the exposure were ‘oat* or barley or beta-glucan or beta glucan or b-glucan or b
glucan’ and terms related to outcome were ‘glycemi* or glycaemi* or glucose or post-prandial or post
prandial or postprandial or post-meal or post meal’. The main exclusion criteria were: the food
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constituent studied was not beta-glucans derived from oats and/or barley; the investigational product
was not administered orally (i.e. it was not consumed); the amount of beta-glucans administered was
not reported and could not be calculated from information provided in the manuscript; the amount of
beta-glucans administered in the test meal was greater than or equal to 4 g per 30 g available
carbohydrates; the food matrix was not a ready-to-eat breakfast cereal manufactured via pressure
cooking (i.e. either batch cooking or extrusion); the outcome measures were not related to post-
prandial glucose and insulin responses; the independent effects of the oat or barley beta-glucans could
not be determined; and the amount of available carbohydrates in the active and control test meals
differed by more than 15% or was not reported.
No limitations were placed on the literature search with respect to the publication date or language.
No pertinent human intervention studies were retrieved by the search. The applicant submitted two
unpublished human intervention studies as pertinent to the health claim (SUGiRS, 2018 unpublished
and SUGiRS, 2019, unpublished). Both studies were conducted by the same research group in
Australia at the Sydney University’s Glycaemic Index Research Service (SUGiRS).
In a one-centre, randomised, double-blind, cross-over, placebo-controlled, positive-controlled study
(SUGiRS 2018, unpublished and claimed as proprietary by the applicant), post-prandial blood glucose
and insulin concentrations were measured over a 2-h period in 15 subjects. The study was conducted
using an internationally recognised glycaemic index methodology (Joint FAO/WHO Report, 1998,
International Standard®; ISO/FDIS 26642:2010). Upon a request from EFSA on the reasons for the
enrolment of 15 participants in the study rather than 10, a number usually used in glycaemic index
studies, the applicant clarified that a higher number of participants were recruited to account for the
inter- and intra-individual variability in glucose responses and attrition.
Non-smoking subjects with normal body mass index (BMI; 18–25 kg/m2) of both sexes, aged 25–60
years were recruited from the staff and student population of the research centre. Non-inclusion
criteria were dieting, impaired glucose tolerance, suffering from any illness or food allergy and regular
use of prescription medication other than standard contraceptive medication.
Six batch-cooked and two extruded products were tested. These included six batch-cooked ready-
to-eat breakfast cereals with no or added beta-glucans from oats (n = 3; at doses of 0, 1.2 and 1.6 g
of added beta-glucans per 25 g of available carbohydrates) or barley (n = 3; at doses of 0.8, 0.9 and
1.4 g of added beta-glucans per 25 g of available carbohydrates). In addition, two extruded breakfast
cereals with beta-glucans from oats at doses of 0 and 1.2 g per 25 g of available carbohydrates,
respectively, were tested. All products were consumed with 250 mL of water. Pure glucose (25.7 g)
dissolved in water was used as the reference food and was consumed by each participant on three
separate occasions.
Participants were assigned a randomisation number in chronological order of inclusion from the
randomisation list.
Glucose was consumed on the first, sixth and 11th test sessions, and the eight breakfast cereals
were consumed in random order in between. Each test session was completed on a separate morning
with at least one day between sessions. The applicant was asked to clarify whether the washout
period between two consecutive tests was adequate to minimise the impact of the previous test
session on the results of the next session. In response, the applicant submitted the study by Mettler
et al. (2009) showing that the incremental areas under the curve (iAUC)0-120min of blood glucose
concentrations did not differ significantly between the short and long intervals (consecutive days and
5- to 10-day intervals, respectively) and that the variability of the blood glucose iAUC0-120min was not
influenced by the time span between the tests.
Study participants and investigators were blinded to the composition of the test products
throughout the study (including data collection and analysis). Within a given study, test foods had
almost identical appearance, so it was not possible for participants or investigators to detect
differences between the test products by sight. Upon a request from EFSA, the applicant clarified that
researchers preparing the test portions were blinded to the composition of the test products and the
potential differences between the cereals. The applicant also clarified that even if the participants
could detect differences in textures and taste between the test products, this should not have
influenced the results as the order of the visits was randomised and the endpoints measured were
assessed using objective methods.
During each test session, blood glucose and insulin concentrations were measured eight times over
2 h (twice at baseline, and once at 15, 30, 45, 60, 90 and 120 min) after consuming the meals. Blood
glucose concentrations were analysed in duplicate using a glucose hexokinase enzymatic assay and an
automatic centrifugal spectrophotometric clinical chemistry analyser. Serum insulin concentrations were
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analysed using a commercial insulin sandwich type enzyme-linked immunoassay. The iAUC of plasma
glucose and insulin responses were calculated, with fasting levels as baselines. Dietary, exercise,
medication and lifestyle habits of the participants were assessed at each study visit to ensure that
participants maintained their usual dietary and lifestyle habits throughout the study duration.
The primary outcome of the study was to establish the glycaemic index (GI) and the insulinaemic
index (II) of the eight breakfast cereals tested using glucose as reference. The secondary objective
was to compare the glycaemic and insulinaemic responses (iAUC) to the consumption of the eight
breakfast cereals differing in the manufacturing process and in the amount of beta-glucans added.
Additionally, peak plasma glucose (Cmax) and maximum glucose concentration time (Tmax) were
measured.
For the statistical analyses of the glycaemic and insulinaemic responses (iAUC), two different data
sets were created. The first included data for batch-cooked cereals (containing 0, 0.8, 0.9, 1.2, 1.4
and 1.6 g of beta-glucans) and for the glucose solution. The second included data for the two
extruded breakfast cereals (containing 0 and 1.2 g of beta-glucans) and for the glucose solution.
Paired t-tests comparing the study endpoints for each type of cereal containing beta-glucans against
the same type of cereal without beta-glucans and against the glucose solution were performed. No
adjustment for multiple comparisons was presented in the study report. Upon a request from EFSA,
the applicant provided a re-analysis adjusting the results for multiple comparisons using the
Benjamini–Hochberg procedure controlling for the false discovery rate. The main analysis was
performed on a per protocol (PP) basis. The PP set featured all subjects who tested all products and
who were not considered as outliers for the glucose or insulin iAUC for any of the tested products.
Outlier response was defined as a value more than  two standard deviations (SD) from the group
mean value.
All 15 participants recruited (age 33.8 years, range: 25.2–53.8 years, BMI 23.2 kg/m2, 18.5–24.9
kg/m2) completed the study. For batch-cooked cereals, the results for one participant regarding
glucose response at the test with 0.9 g of beta-glucans per 25 g of available carbohydrates was
classified as an outlier (i.e. had a glucose response  2 SD from the mean). For extruded cereals, the
results of another participant regarding the insulin response to the extruded cereal without added
beta-glucans was classified as outlier (i.e. had an insulin response > +2 SD from the mean). These
subjects were not considered in the PP analysis. Hence, the PP population included 14 participants for
the analyses on batch-cooked cereals and 14 participants for the analyses on extruded cereals for all
outcomes (i.e. glucose and insulin iAUC).
The results adjusted for multiple comparisons showed significantly lower blood glucose and insulin
concentrations (iAUC) following consumption of the two types of breakfast cereals with added beta-
glucans as compared to the same type of breakfast cereals with no added beta-glucans. Exceptions
were the batch-cooked cereal with 0.9 g beta-glucans for glucose iAUC and the batch-cooked cereal
with 0.8 g beta-glucans for insulin iAUC. The Panel notes that, although the study was planned as
dose–response study at least in relation to the content of beta-glucans in batch-cooked breakfast
cereals, dose–response relationships were not assessed.
The Panel considers that this study shows an effect of beta-glucans from oats and/or barley
incorporated into ready-to-eat breakfast cereals manufactured via pressure cooking at a level of at
least 1.2 g per 25 g of available carbohydrates on decreasing post-prandial glycaemic responses,
without disproportionally increasing post-prandial insulinaemic responses. The Panel notes that the
effect was not consistent at doses of beta-glucans < 1.2 g per 25 g of available carbohydrates and
that dose–response relationships between the intake of beta-glucans and post-prandial glycaemic
responses were not tested.
SUGiRS (2019, unpublished and claimed as proprietary by the applicant) is a one-centre,
randomised, double-blind, cross-over, placebo-controlled, positive-controlled study, which investigated
the effects of four ready-to-eat breakfast cereals with oat beta-glucans on post-prandial blood glucose
and insulinaemic responses over a 2-h period. The study was carried out in the same research centre
as the previous study (SUGiRS, 2018, unpublished) and had a similar design, including the same
inclusion and non-inclusion criteria for participation and the same methods used for the measurements
of glucose and insulin concentrations in blood.
Three batch-cooked and three extruded ready-to-eat breakfast cereals, were tested with 125mL of
milk and each meal contained 0g, 1.0g and 1.3g of oat beta-glucans per 25g of total available
carbohydrate. All foods were consumed with 250 mL of water on eight separate sessions: four with
the cereals with added beta-glucans and four with the cereals with no added beta-glucans.
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The applicant provided data in relation to the content of available carbohydrates in all the cereal
meals (breakfast cereals plus 125 mL of low-fat milk) tested. The amount of available carbohydrates
was 28.9 g, 26.9 g and 25.6 g in the batch-cooked cereals containing 0 g, 1.0 g and 1.3 g of beta-
glucans, respectively, and 28.2 g, 25.6 g and 24.9 g in the extruded cereals containing 0 g, 1.0 g and
1.3 g of beta-glucans, respectively. The Panel notes that the amount of available carbohydrates in the
cereals is inversely proportional to the amount of beta-glucans they contain. Thus, it is not possible to
assess whether differences in glucose and insulin responses following the consumption of the cereals
could be attributed to differences in the content of beta-glucans, to differences in the amount of
available carbohydrates, or to a combination of these.
Upon a request from EFSA, the applicant also clarified that randomisation considered only the
cereals containing beta-glucans, but not the cereals without beta-glucans, which were tested twice
each (i.e. at the beginning and end of each study period).
The Panel considers that no conclusions can be drawn from this study with respect to the dose of
beta-glucans in breakfast cereals manufactured via pressure cooking (i.e. either batch cooking or
extrusion) that is required to exert the claimed effect for a given amount of available carbohydrates.
This is because it is not possible to assess whether differences in glucose and insulin responses
following consumption of the ready-to-eat breakfast cereals could be attributed to differences in the
content of beta-glucans, to differences in the amount of available carbohydrates or to a combination of
these, and to which extent. The Panel also notes that the order in which control foods were tested
was not randomised.
The Panel considers that one human intervention study (SUGiRS, 2018, unpublished) shows an
effect of beta-glucans from oats and/or barley, incorporated into ready-to-eat breakfast cereals
manufactured via pressure cooking (i.e. either batch cooking or extrusion) at a level of at least 1.2 g
per 25 g available carbohydrate, on decreasing post-prandial glycaemic responses without
disproportionally increasing post-prandial insulinaemic responses. The Panel notes that the results of
the study by SUGiRS (2018, unpublished) have not been confirmed by other research groups.
Mechanism of action proposed
The applicant claims that the physiological effects of beta-glucans have largely been attributed to
their viscosity generating properties within the gastrointestinal tract and that the manufacturing
processes and cooking techniques can induce structural changes to beta-glucans and alter their
viscosity properties, which in turn could influence their effects on the glycaemic response (Henrion
et al., 2019).
The applicant provided a report (Hyyti€ainen-Pabst et al., 2019 unpublished, claimed as proprietary
by the applicant) in which an in vitro model of the upper gastrointestinal tract was used to investigate
the physico-chemical properties of beta-glucans in processed cereal samples and in raw materials used
in the manufacture of these processed cereals. The processed cereals tested included the batch-
cooked and extruded cereals investigated in the SUGiRS 2018 study, but also porridges and granola-
type cereals. The Panel notes that the total amount of beta-glucans in the test samples varied widely
across raw materials and processed cereals. To produce ‘physiological extracts’, samples were
incubated in simulated salivary fluid (pH 7.0) (oral phase), followed by simulated gastric fluid (pH 3.0)
together with pepsin (gastric phase) and lastly in simulated intestinal fluid (pH 7.0) with porcine bile
extract, pancreatin and additional lipase from porcine pancreas (duodenal phase). The percentage of
beta-glucans that could be extracted from processed cereal products of all types into the ‘physiological
extract’ was higher than the percentage of extractable beta-glucans from their non-processed raw
materials. Viscosity of the ‘physiological extracts’ obtained from the processed cereals with added oats
or barley beta-glucans was measured after removing insoluble particles by centrifugation in the
supernatant and compared with the viscosity of ‘physiological extracts’ obtained from the same
processed cereals without added beta-glucans. The viscosity in the supernatant was higher for the
batch-cooked and extruded cereals with added oats or barley beta-glucans than for the ones without
beta-glucans. The viscosity in the supernatant from the granola-type cereal with oat beta-glucans was
higher than the one from granola-type cereal without beta-glucans; the difference was less
pronounced for barley beta-glucans. There was no difference in the viscosity in the supernatants of
porridge produced with and without beta-glucans.
The Panel considers that this study does not provide evidence that beta-glucans incorporated into
ready-to-eat cereals processed using batch cooking or extrusion would exert a greater effect on the
reduction of post-prandial glucose responses than beta-glucans added to other foods not
manufactured via pressure cooking and containing similar amounts of available carbohydrate.
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Weighing the evidence
In weighing the evidence, the Panel took into account that one human intervention study showed
an effect of beta-glucans from oats and/or barley, incorporated into ready-to-eat breakfast cereals
manufactured via pressure cooking (i.e. either batch cooking or extrusion) at a level of at least 1.2 g
per 25 g available carbohydrate, on decreasing post-prandial glycaemic responses without
disproportionally increasing post-prandial insulinaemic responses. However, the Panel also considered
that only one study from which conclusions could be drawn is available, and that dose–response
relationships between the concentration of beta-glucans in ready-to-eat breakfast cereals and post-
prandial glucose responses were not tested. No evidence has been provided that beta-glucans
incorporated into ready-to-eat cereals processed using pressure cooking would exert a higher effect on
the reduction of post-prandial glucose responses than beta-glucans added to other carbohydrate
containing foods (i.e. and thus that the dose of beta-glucans required to exert the claim effect per a
given amount of digestible carbohydrates would be lower).
The Panel concludes that, whereas the effect of beta-glucans in reducing post-prandial blood
glucose responses is well established, the evidence provided is insufficient to establish such an effect
at doses of 1.3 g beta-glucans per 25 g of available carbohydrate incorporated into ready-to-eat
breakfast cereals manufactured via pressure cooking (i.e. either batch cooking or extrusion), as
requested by the applicant.
Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, beta-glucans from oats, barley or any combination thereof, incorporated
into ready-to-eat cereals manufactured by pressure cooking, which is the subject of the health
claim, is sufficiently characterised.
• The claimed effect proposed by the applicant is ‘reduction of the blood glucose rise after the
meal’. The target population proposed by the applicant is the general population. Reduction of
post-prandial glycaemic responses (as long as post-prandial insulinaemic responses are not
disproportionally increased) may be a beneficial physiological effect.
• The effect of beta-glucans in reducing post-prandial blood glucose responses is well
established. However, the evidence provided is insufficient to establish an effect on reduction of
post-prandial glycaemic responses at doses of 1.3 g beta-glucans per 25 g of available
carbohydrate incorporated into ready-to-eat breakfast cereals manufactured by pressure
cooking (i.e. either batch cooking or extrusion), as requested by the applicant.
Documentation as provided to EFSA
Health claim application on beta-glucans from oats and/or barley in a ready-to-eat cereal
manufactured via pressure cooking and reduction of blood glucose rise pursuant to Article 13(5) of
Regulation (EC) No 1924/2006 (Claim serial No: 0497_BE). Submitted by Nestle S.A., Avenue Nestle 55
CH-1800 Vevey, Switzerland.
Steps taken by EFSA
1) This application was received by EFSA on 10/06/2020.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 21/09/2020.
4) On 8/10/2020, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The scientific
evaluation was suspended on 27/10/2020 and was restarted on 11/11/2020, in compliance
with Article 18(3) of Regulation (EC) No 1924/2006.
5) During its meeting on 25/02/2021, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to the consumption of beta-
glucans from oats and/or barley in a ready-to-eat cereal manufactured via pressure cooking
and reduction of blood glucose rise.
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